Left to Right: Graham Bell and David Quigley of Edinburgh Biosciences (Photo by Stewart Attwood)

Top story from Biotech

Edinburgh-based medtech company Edinburgh Biosciences , the company behind a revolutionary new non-surgical treatment for cataracts has received a £2.3m

Facebook
Twitter
LinkedIn

Other Stories in Biotech

Edinburgh medtech firm secures £2.3m to bring cataract care into focus
Opinion Piece: The cybersecurity cost of spit-in-a-tube science
Compostable sensors could help grow impact of digital agriculture
digitizing drug development process
Strathclyde Uni project aims to digitise drug development
Avacta Group strengthens executive team with appointment of Michelle Morrow, PhD as Chief Scientific Officer
Distillery announces long-term partnership with biotech firm

Subscribe to our daily newsletter

Why? Free to subscribe, no paywall, daily business news digest.

Our Brand Sites